IMIDEX

Wes Bolsen will be at the #JPM Healthcare conference in San Francisco from January 13-16 to continue conversations that started at #RSNA on the acquisition of IMIDEX. With a US Patent, and one of the broadest FDA 510(k) cleared algorithms for the screening and incidental detection of lung nodules and masses from chest x-ray, this will be an industry leading solution for the early detection of lung cancer. If there is interest in rolling up this leading technology as part of your company or platform, please reach out directly for a meeting at #JPM as we enter final conversations.

IMIDEX being highlighted at the Radiological Society of North America (RSNA) for having the leading FDA 510(k) cleared solution for detecting lung nodules and masses from chest x-rays. Reach out to Wes Bolsen if you would like to meet up and discuss. #RSNA #LungCancer #AI

Wes Bolsen will be meeting with potential acquirers at the Radiological Society of North America (RSNA) conference in Chicago. If you are attending #RSNA and interested in meeting, please reach out to Wes!

Exciting news! IMIDEX will be meeting with potential acquirers at #RSNA in a final opportunity to acquire the patents, FDA 510(k) algorithm and annotated dataset behind the leading AI solution for lung nodule and mass detection from chest x-rays. Reach out for a meeting! https://lnkd.in/gixpHMSG

IMIDEX is proud to support Lung Cancer Awareness Month.?Early detection of lung cancer is now possible through the use of AI Imaging on chest x-rays. Incidental detection as well as affordable community wide screening of lung nodules and masses will be the future. ?Radiologists can go from finding 50% of the lung nodules and masses to 83% in a matter of seconds! ?#LCAM #lungcancer

Joining forces with ground-breaking companies like Orbit Genomics who share our goal of saving lives lost to lung cancer is why we do what we do. Whether it's identifying incidental patients or backing new, low-cost chest x-ray screening programs, our VisiRad XR software has the power to identify millions of patients with pulmonary nodules that are currently missed. Combining those identified patients with the precision genomics capabilities offered by Orbit's OrbiSeq-L platform can have a massive impact on lung cancer identification and patient outcomes. https://lnkd.in/gQD5JCT3

Joining forces with ground-breaking companies like Orbit Genomics who share our goal of saving lives lost to lung cancer is why we do what we do. Whether it's identifying incidental patients or backing new, low-cost chest x-ray screening programs, our VisiRad XR software has the power to identify millions of patients with pulmonary nodules that are currently missed. Combining those identified patients with the precision genomics capabilities offered by Orbit's OrbiSeq-L platform can have a massive impact on lung cancer identification and patient outcomes. https://lnkd.in/gQD5JCT3

Excited to announce our partnership and the launch of a clinical study with Spesana! We're both passionate about improving lung cancer detection and care, and through this collaboration we're taking the next step forward towards improving outcomes for patients. Thanks to Carla Balch Justin J. Friedly and Bobbi Coffin for helping us pull this together. Onwards! https://lnkd.in/gg5CCemJ

Joining forces with ground-breaking companies like Orbit Genomics who share our goal of saving lives lost to lung cancer is why we do what we do. Whether it's identifying incidental patients or backing new, low-cost chest x-ray screening programs, our VisiRad XR software has the power to identify millions of patients with pulmonary nodules that are currently missed. Combining those identified patients with the precision genomics capabilities offered by Orbit's OrbiSeq-L platform can have a massive impact on lung cancer identification and patient outcomes. https://lnkd.in/gQD5JCT3

Our recent whitepaper details the success of VisiRad XR in detecting lung nodules and masses on real patient data from emergency departments and outpatient facilities. Tangible results, like VisiRad's 82% sensitivity achieved on chest X-rays from our partners at Billings Clinic, demonstrate the real-world effectiveness of AI detection in radiology. Over 40% of the nodules VisiRad XR identified in our study with Billings Clinic were less than 11mm in size. A huge opportunity to identify often-overlooked critical findings!